The market value of cell therapy products in the U.S. stands at an estimated $4.5 billion and is expected to increase to over $30 billion in the next decade. It is apparent that as this market value surges, the industry is likely to witness an escalation in litigation. As legal professionals, we must be aware of the significant implications this projected surge could have on patent law.
A recent development potentially impacting the scope of issued patents pertains to prosecution estoppel potentially being created in child cases. To appreciate the gravity of this advancement, a proper understanding of prosecution estoppel is crucial. This principle stems from the notion that an applicant, having narrowed their patent claims to obtain issuance, should be prohibited from later reasserting the broader scope initially requested. This inhibition creates a barrier; one that may limit the understanding of the patent scope.
An intriguing factor in this narrative is the role of ‘child cases’, a term used for subsequent applications related to an original ‘parent application’. As these subsequent claims can effectively extend the length and scope of the patent, this may give root to potential legal complications that can, in turn, affect the sustainability of patent holdings.
Though it is undoubtedly a complex topic, practitioners must acknowledge the role changes in patent prosecution can play in shaping the landscape for future patent disputes. This development could significantly impact both the strategy for applying for a patent and the potential for defending that patent in court.
For a thorough understanding of why the scope of issued patents may be limited by prosecution estoppel created in child cases, you can refer to this comprehensive article on
JD Supra.